SCHEMBL5568397

SCHEMBL5568397

Clc1ccc(Nc2ncnc3ccccc23)c(Cl)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 10/20 0.68
FADS1 O60427 1/20 0.68
LCK P06239 1/20 0.66
SRC P12931 1/20 0.62
DYRK1A Q13627 2/20 0.58
ABCG2 Q9UNQ0 4/20 0.58
DAPK3 O43293 1/20 0.58
MAP4K4 O95819 1/20 0.58
ABL1 P00519 1/20 0.58
ERBB2 P04626 1/20 0.58
PIM1 P11309 1/20 0.58
PRKACA P17612 1/20 0.58
LTK P29376 1/20 0.58
MAPK8 P45983 1/20 0.58
CSNK1A1 P48729 1/20 0.58
RPS6KA3 P51812 1/20 0.58
LIMK1 P53667 1/20 0.58
MAP2K1 Q02750 1/20 0.58
ACVR1 Q04771 1/20 0.58
TYRO3 Q06418 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5564798 0.86 EGFR (0.60) EGFRFADS1LCKDYRK1AABCG2
SCHEMBL5569110 0.86 EGFR (0.60) EGFRFADS1LCKSRCDYRK1A
SCHEMBL9017045 0.84 TTBK1 (0.61) EGFRFADS1LCKDYRK1AABCG2
SCHEMBL5568040 0.83 EGFR (0.60) EGFRFADS1LCKDYRK1AABCG2
SCHEMBL11092575 0.82 EGFR (0.63) EGFRFADS1LCKSRCDYRK1A
SCHEMBL11091920 0.82 TTBK1 (0.59) EGFRFADS1LCKSRCAURKB
SCHEMBL5566231 0.82 SRC (0.65) EGFRSRCDYRK1AERBB2GLA
SCHEMBL14027230 0.81 EGFR (0.75) EGFRFADS1LCKDYRK1AABCG2
Hydrochloric Acid SCHEMBL11089555 0.81 TTBK1 (0.58) EGFRFADS1LCKSRCAURKB
Hydrochloric Acid SCHEMBL11088198 0.81 EGFR (0.62) EGFRFADS1LCKSRCDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US claimed
EP-1673346-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC Biotech AG (DE) 2006-06-28 EP claimed
WO-2005040125-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC BIOTECH AG (DE) 2005-05-06 WO claimed
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US disclosed
EP-1673346-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC Biotech AG (DE) 2006-06-28 EP disclosed
WO-2005040125-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC BIOTECH AG (DE) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections IRF3, PML, TPMT EGFR 1445/4885FADS1 4484/4885LCK 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.